Latest News & Features
Refine Search
Asia-Pacific
China, Japan and South Korea are three of the most developed markets in the world for pharmaceuticals but they still offer a wealth of opportunities for both innovators and generic drug companies. LSIPR looks at the protection available for those seeking to do business there. 20 June 2014
Americas
The patent regulatory framework in Mexico needs to evolve if the investment in, and marketing of, promising biotechnology drug products is to succeed, says Hector E. Chagoya. 20 June 2014
Americas
The effect of obviousness-type double patenting on patent term extension and patent term adjustment in the biotech and pharma industry needs careful consideration, as Gaby L. Longsworth and Eric K. Steffe report. 20 June 2014
Biotechnology
For those involved in the development of biological drugs, the prospects of getting what would seem to be a ‘fair reward’ may not have improved much, says Jaap Mannaerts. 20 June 2014
Biotechnology
The exclusion from patentability of certain cells derived from human embryos is a reflection of the EPO’s increasingly restrictive stance, say Franz-Josef Zimmer and Markus Grammel. 20 June 2014
Asia
Recent decisions suggest that the Indian system seems to be changing direction towards developing sound patent law jurisprudence, says Archana Shanker. 20 June 2014
Biotechnology
Digital health, which brings together digital and genetic data to improve healthcare, will play a vital role in personalised medicine. But there will be significant challenges when it comes to protecting this innovative new area. LSIPR looks at its uses and the potential challenges. 20 June 2014
Biotechnology
The USPTO’s new guidance for examiners extends the decision in Myriad beyond isolated nucleic acids to all claims concerning ‘judicial exceptions’. Bethan Hopewell and Jennifer Antcliff report. 20 June 2014
Americas
Acting against infringers can involve the pharmaceutical regulatory framework and civil law as well as following the more usual pathways, says José R. Trigueros. 20 June 2014
Genetics
The realm of patent eligibility under 35 USC §101 has become more confusing, with the introduction of a possible new definition of admissibility after a decision on Dolly the sheep. Nabeela Rasheed reports. 20 June 2014